Cases & Deals

Jazz Pharmaceuticals acquires EUSA Pharma for $650 million

Client(s) Jazz Pharmaceuticals, Inc.

Jones Day acted as IP counsel in advising Jazz Pharmaceuticals, Inc. in connection with the execution of a definitive agreement under which Jazz Pharmaceuticals has agreed to acquire EUSA Pharma for $650 million in cash and a potential $50 million milestone payable in cash based upon Erwinaze™ achieving a specified U.S. net sales target in 2013.